SCHEMBL5224397

SCHEMBL5224397

COc1ccc(CCN)c([N+](=O)[O-])c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.54
ADRA1A P35348 1/20 0.54
ALDH1A1 P00352 3/20 0.50
MAPK1 P28482 3/20 0.50
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPT P10636 5/20 0.47
HTR2A P28223 2/20 0.47
CYP1A2 P05177 1/20 0.47
HTR1A P08908 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
HTR1D P28221 1/20 0.47
HTR1B P28222 1/20 0.47
HTR2C P28335 1/20 0.47
HTR7 P34969 1/20 0.47
HTR6 P50406 1/20 0.47
HTR4 Q13639 1/20 0.47
TRPM8 Q7Z2W7 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL11258422 0.98 TAAR1 (0.53) TAAR1ADRA1AALDH1A1MAPK1RAB9A
SCHEMBL4233857 0.91 ALDH1A1 (0.48) TAAR1ADRA1AALDH1A1MAPK1RAB9A
SCHEMBL2259328 0.89 TAAR1 (0.57) TAAR1ADRA1AALDH1A1MAPK1RAB9A
SCHEMBL430628 0.89 ALDH1A1 (0.51) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL3823448 0.85 ALDH1A1 (0.54) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL3576116 0.84 ALDH1A1 (0.51) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL11258390 0.84 MAPT (0.45) ALDH1A1MAPTCYP1A2HTR1ATSHR
SCHEMBL2946382 0.84 ALDH1A1 (0.51) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL3574940 0.84 ALDH1A1 (0.50) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2
SCHEMBL28712089 0.83 ALDH1A1 (0.53) ALDH1A1MAPK1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1869041-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA Warner-Lambert Company LLC (US) 2007-12-26 EP disclosed
EP-1567488-B1 HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE GLAXO GROUP LTD (GB) 2007-02-21 EP disclosed
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia WARNER-LAMBERT COMPANY LLC 2006-10-19 US disclosed
WO-2006103559-A1 TETRAHYDRO-PYRIDOAZEPIN-8-ONES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA WARNER-LAMBERT COMPANY LLC (US) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060234997-A1 Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia PTGDR, GRIN2A, PTGDR2 TAAR1 263/4885ADRA1A 227/4885ALDH1A1 826/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.